Cipla's InvaGen New York facility gets USFDA No Action Indicated
In short
Cipla said the USFDA gave InvaGen Pharmaceuticals’ New York facility a No Action Indicated result. The inspection was held from October 19 to October 22, 2026, and the result was communicated on November 17.
This is good for Cipla because it points to a clean regulatory outcome for the plant. It may help support operations at the facility.
What the reporting says
Cipla said the USFDA classified the inspection of InvaGen Pharmaceuticals’ manufacturing facility in New York as No Action Indicated. The inspection took place from October 19 to October 22, 2026, and the classification was communicated on November 17. The outcome is a regulatory clearance for the facility and may ease compliance concerns for the company.
Why it matters
Cipla said the USFDA classified the inspection of InvaGen Pharmaceuticals’ manufacturing facility in New York as No Action Indicated. The inspection was conducted from October 19 to October 22, 2026, and the result was communicated on November 17. The classification is a favorable regulatory outcome for the pharmaceutical company and its manufacturing site.